FY2025 EPS Estimates for Alkermes Reduced by Leerink Partnrs

Alkermes plc (NASDAQ:ALKS) – Research analysts at Leerink Partnrs decreased their FY2025 earnings per share estimates for Alkermes in a research report issued on Wednesday, January 29th. Leerink Partnrs analyst M. Goodman now anticipates that the company will earn $1.50 per share for the year, down from their prior estimate of $1.55. The consensus estimate for Alkermes’ current full-year earnings is $2.23 per share. Leerink Partnrs also issued estimates for Alkermes’ FY2026 earnings at $1.84 EPS.

A number of other equities analysts also recently commented on ALKS. Cantor Fitzgerald lowered their price objective on Alkermes from $48.00 to $43.00 and set an “overweight” rating for the company in a research report on Friday, October 25th. Piper Sandler reiterated an “overweight” rating and set a $37.00 price target (down previously from $38.00) on shares of Alkermes in a report on Friday, October 25th. The Goldman Sachs Group reduced their price objective on shares of Alkermes from $32.00 to $30.00 and set a “buy” rating on the stock in a report on Friday, October 25th. JPMorgan Chase & Co. lowered their target price on shares of Alkermes from $32.00 to $26.00 and set a “neutral” rating for the company in a research note on Friday, October 25th. Finally, Mizuho raised their price target on Alkermes from $35.00 to $40.00 and gave the company an “outperform” rating in a research note on Wednesday, November 13th. One analyst has rated the stock with a sell rating, two have issued a hold rating and nine have assigned a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $36.00.

Alkermes Trading Down 1.2 %

ALKS opened at $31.53 on Thursday. The business has a fifty day moving average price of $29.82 and a 200 day moving average price of $28.27. The company has a debt-to-equity ratio of 0.22, a current ratio of 3.45 and a quick ratio of 3.03. Alkermes has a 12 month low of $22.90 and a 12 month high of $32.88. The stock has a market capitalization of $5.10 billion, a price-to-earnings ratio of 16.17, a PEG ratio of 1.68 and a beta of 0.49.

Insider Activity at Alkermes

In other Alkermes news, EVP Craig C. Hopkinson sold 10,471 shares of the business’s stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $29.53, for a total value of $309,208.63. Following the completion of the sale, the executive vice president now owns 99,238 shares in the company, valued at approximately $2,930,498.14. The trade was a 9.54 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Christian Todd Nichols sold 5,208 shares of the firm’s stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $29.15, for a total transaction of $151,813.20. Following the transaction, the senior vice president now owns 60,703 shares in the company, valued at approximately $1,769,492.45. This trade represents a 7.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 248,656 shares of company stock valued at $7,807,326 in the last three months. 4.89% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Alkermes

Hedge funds have recently made changes to their positions in the business. CIBC Asset Management Inc raised its stake in Alkermes by 4.4% during the 4th quarter. CIBC Asset Management Inc now owns 9,155 shares of the company’s stock valued at $263,000 after acquiring an additional 384 shares during the last quarter. Handelsbanken Fonder AB raised its stake in shares of Alkermes by 0.3% during the third quarter. Handelsbanken Fonder AB now owns 220,600 shares of the company’s stock worth $6,175,000 after purchasing an additional 700 shares during the last quarter. Nicollet Investment Management Inc. lifted its holdings in shares of Alkermes by 1.7% during the third quarter. Nicollet Investment Management Inc. now owns 43,845 shares of the company’s stock worth $1,227,000 after purchasing an additional 714 shares during the period. KBC Group NV lifted its holdings in shares of Alkermes by 18.8% during the third quarter. KBC Group NV now owns 4,890 shares of the company’s stock worth $137,000 after purchasing an additional 774 shares during the period. Finally, Venturi Wealth Management LLC purchased a new position in Alkermes in the 4th quarter valued at $25,000. Institutional investors and hedge funds own 95.21% of the company’s stock.

Alkermes Company Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.